Articles related to MEDICAL MEETINGS AND EVENTS

Explore the profound impact of Social Determinants of Health on mantle cell lymphoma outcomes and the potential of novel therapies in reducing these disparities.

The future of advanced bladder cancer treatment has been crystallized by the findings of the EV302 study, which demonstrated a median overall survival of 31.5 months with enfortumab vedotin-ejfv plus pembrolizumab.

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.

The study’s findings suggest that palliative radiotherapy could be a viable option for managing pain in multiple myeloma patients. With a complete response rate of 48% and a partial response rate of 38%, this treatment approach shows promise.

The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.

Explore innovative options for patients with pancreas, liver and biliary cancers at the Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023.